Abstract

Celiprolol (Celectol – Rhoône Poulenc Rorer) is a new cardioselective β-blocker and vasodilator, intended for once daily treatment of mild to moderate hypertension. The manufacturer claims that “it improves the overall cardiovascular risk profile” and gives hypertensive patients “a better quality of life than can be expected from conventional β-blocker treatment”. We examine these claims.